← All trials
NCT02754765
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2016
- Primary completion
- Sep 1, 2020
- Completion date
- Apr 1, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 750
- Arms / groups
- 6 / —
- Source
- AACT · pre-existing
Sponsors
- Medecins Sans FrontieresLead sponsor
- Partners in HealthCollaborator
- EpicentreCollaborator
- Institute of Tropical Medicine, BelgiumCollaborator
- National Center for Tuberculosis Problems, KazakhstanCollaborator
- National Center for Tuberculosis and Lung Diseases, GeorgiaCollaborator
- Socios En Salud, PeruCollaborator
- Government of KyrgyzstanCollaborator
- Government of LesothoCollaborator
- Harvard UniversityOverall official - principal investigator
- Harvard UniversityCollaborator
- Medecins Sans FrontieresOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.